{
  "id": "blood-transfusion",
  "title": "Blood Transfusion",
  "lang": "en",
  "source_lang": "en",
  "summary": "Blood transfusion replaces blood or its components to support oxygen delivery, control bleeding, and treat selected medical conditions.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Transfusion of blood"
  ],
  "generated_at": "2026-10-22",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/blood-transfusion/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/blood-transfusion/",
      "json": "https://aiwiki.page/zh/blood-transfusion.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Blood transfusion is the administration of donated whole blood or blood components into a person’s circulation, usually through a vein. Different components serve different purposes: red blood cells restore oxygen-carrying capacity, platelets support clot formation, and plasma supplies coagulation factors. Transfusion is an important treatment for major bleeding, selected cases of anemia, and disorders affecting blood production or clotting, and it supports surgery, childbirth care, and cancer treatment. (professionaleducation.blood.ca)\n\nModern transfusion depends on an interconnected system of donor recruitment, blood collection, testing, processing, storage, compatibility assessment, and patient monitoring. The ABO blood group system and other blood-group antigens are central to compatibility, while donor screening and laboratory testing reduce infectious risks. Transfusion nevertheless carries immune, infectious, circulatory, and metabolic risks, making both product quality and the clinical transfusion process essential to safety. (professionaleducation.blood.ca)\n\nThe field developed through discoveries in blood circulation, blood groups, anticoagulation, and preservation. Its present scope includes specialized transfusion techniques, surveillance of adverse events, equitable access to blood supplies, and patient blood management—a coordinated approach addressing anemia, blood loss, and coagulation disorders while limiting unnecessary transfusion. Research also investigates laboratory-grown red blood cells and their potential applications. (aabb.org)"
    },
    {
      "heading": "Blood Components and Their Physiological Functions",
      "text": "Whole-blood transfusion delivers red cells, plasma, and platelets together in a collected blood preparation; component transfusion delivers selected constituents separately, allowing oxygen-carrying cells and hemostatic materials to be supplied independently. Allogeneic transfusion uses blood from another person, whereas autologous transfusion returns a patient’s own blood, whether collected beforehand or recovered during surgery. These blood components differ from manufactured plasma-derived medicines: albumin, immunoglobulins, and plasma-derived coagulation-factor concentrates are purified from donated plasma through industrial fractionation rather than supplied as intact cellular components or unfractionated plasma. (redcrossblood.org)\n\nRed blood cells principally restore oxygen-carrying capacity. Their hemoglobin binds oxygen in the lungs and transports it to tissues; transfusion increases the circulating mass of this oxygen-binding protein. This is distinct from restoring circulating fluid volume: a fluid infusion can expand the circulation without supplying hemoglobin. Conversely, red-cell transfusion adds volume but is not primarily a volume-replacement treatment. Oxygen delivery also depends on cardiovascular function, so an increase in hemoglobin concentration does not by itself establish adequate tissue oxygenation. As a quantitative illustration, Canadian Blood Services’ 2025 clinical guide states that one red-cell unit usually raises hemoglobin by approximately 10 g/L in a 70-kg adult who is not bleeding. (hematology.org)\n\nPlatelet concentrates support primary hemostasis, the initial formation of a plug at a damaged blood vessel. Platelets are small cell fragments that adhere at the injury site, gather together, and provide a surface on which coagulation reactions can occur. Their transfusion supplies functional platelets when platelet numbers or function are inadequate. Plasma, by contrast, is the liquid portion of blood, carrying proteins, salts, nutrients, and other dissolved substances. Transfused plasma supplies a broad mixture of coagulation factors rather than a concentrated population of cells; it therefore supports clot formation through a different mechanism from either platelet or red-cell transfusion. (hematology.org)\n\nCryoprecipitate is a concentrated, cold-insoluble fraction of plasma containing fibrinogen, factor VIII, factor XIII, von Willebrand factor, and fibronectin. Fibrinogen provides the precursor material for the fibrin framework of a clot, making fibrinogen replacement its principal contemporary transfusion role. Cryoprecipitate is not equivalent to plasma: it concentrates selected proteins rather than retaining the full plasma protein mixture. Nor is it identical to manufactured fibrinogen concentrate, which is purified and standardized. Product composition varies; the Canadian Blood Services guide published in 2025 describes a typical cryoprecipitate unit as approximately 10 mL containing 366 mg of fibrinogen. (redcrossblood.org)\n\nWhole blood combines oxygen-carrying red cells with plasma and platelets and is used in selected settings of major hemorrhage, including trauma, where several functions require simultaneous replacement. Granulocyte components serve a different purpose: they supply infection-fighting white blood cells, predominantly neutrophils. They are sometimes used as adjunctive support for severe bacterial or fungal infection that persists despite antimicrobial treatment in patients with profound neutropenia or defective neutrophil function, particularly when recovery of the patient’s own neutrophils is expected. Their clinical benefit remains uncertain, and they are not routine substitutes for antimicrobial therapy. A granulocyte component cannot correct anemia, just as red cells cannot replace missing coagulation factors and plasma cannot restore a deficient platelet population. (redcrossblood.org)"
    },
    {
      "heading": "Historical Development",
      "text": "William Harvey’s published account of blood circulation in 1628 provided the physiological framework for experiments in transferring blood between individuals. In 1665, the English physician Richard Lower demonstrated that blood from one dog could sustain another after blood loss. In 1667, Jean-Baptiste Denis in France performed animal-to-human transfusions using lamb’s blood; Lower and Edmund King conducted similar experiments in England. Reports of apparent recovery were followed by serious reactions, and animal-to-human transfusion was prohibited in several jurisdictions within the following decade. These experiments established the possibility of transferring blood through vascular connections, but not the safety of crossing species boundaries. (aabb.org)\n\nThe British obstetrician James Blundell revived clinical interest in human-to-human transfusion through work beginning in 1818, particularly in response to fatal obstetric hemorrhage. He developed instruments for collecting and injecting human blood rather than using animal donors. Between 1825 and 1830, he reported ten transfusions, five described as beneficial. Two distinct obstacles remained: blood could clot during collection and transfer, while apparently similar human blood could produce incompatible reactions. Rapid transfer and specially designed apparatus addressed the first problem only imperfectly; donor selection could not reliably address the second before blood groups were understood. (aabb.org)\n\nKarl Landsteiner’s observations in 1900–1901 supplied a basis for distinguishing compatible from incompatible human blood. He identified three groups, initially designated A, B, and C, with C subsequently renamed O; Alfred von Decastello and Adriano Sturli described AB in 1902. The resulting ABO blood-group system made laboratory compatibility testing possible. In 1907, Ludvig Hektoen proposed testing donor and recipient blood together to exclude incompatible mixtures, and Reuben Ottenberg applied blood grouping and crossmatching clinically. Compatibility therefore became something that could be investigated before transfusion rather than inferred from the recipient’s subsequent reaction. (aabb.org)\n\nAnticoagulation and preservation subsequently separated donation from immediate administration. Albert Hustin demonstrated a method of preventing coagulation outside the body in 1914; Richard Lewisohn’s work with sodium citrate in 1915 and Richard Weil’s refrigerated-storage experiments advanced indirect transfusion. In 1916, Francis Peyton Rous and J. R. Turner introduced a citrate–glucose solution that allowed collected blood to be stored for several days. During World War I, Oswald Hope Robertson organized stored-blood depots serving military casualties. Instead of locating a donor beside each wounded patient, medical services could collect blood beforehand and distribute a refrigerated reserve. (nhsbt.nhs.uk)\n\nBlood banking expanded into permanent institutions during the interwar years: Bernard Fantus established a hospital blood bank at Chicago’s Cook County Hospital in 1937. World War II then increased the scale of collection, processing, and distribution. In 1940, Charles R. Drew helped organize Blood for Britain and subsequently standardized participating hospitals’ collection equipment, procedures, records, and bacteriological quality checks. By its conclusion in January 1941, the program had collected 14,556 donations and shipped more than 5,000 litres of plasma–saline solution to England. Britain established its National Blood Transfusion Service in 1946, linking regional blood centres within a national organization. (nlm.nih.gov)\n\nPostwar developments supported component therapy and more formal quality assurance. Plastic collection bags, introduced in 1950, and refrigerated centrifugation facilitated separation of donations into multiple components; platelet concentrates gained recognition for reducing hemorrhagic mortality in patients with cancer in 1961. AABB formed an inspection and accreditation committee in 1957 and published its first transfusion-service standards in 1958. Infectious-disease screening developed alongside these organizational controls: United States milestones included hepatitis B surface-antigen testing in 1971, HIV antibody screening in 1985, specific hepatitis C testing in 1990, and investigational nucleic-acid testing for HIV and hepatitis C in 1999. (aabb.org)"
    },
    {
      "heading": "Clinical Uses and Assessment of Benefit",
      "text": "In traumatic, surgical, gastrointestinal, and obstetric hemorrhage, transfusion supports oxygen delivery and hemostasis while the source of bleeding is controlled. Rapid blood loss differs from stable anemia because circulating volume, red-cell mass, and coagulation capacity may deteriorate together. Assessment therefore includes the rate and estimated extent of bleeding, circulatory stability, and repeated laboratory measurements rather than an isolated hemoglobin concentration. Major hemorrhage may require red cells, platelets, plasma, and fibrinogen replacement; component selection addresses both blood loss and evolving coagulation abnormalities. By contrast, slowly developing anemia permits physiological compensation, and a stable patient may tolerate a hemoglobin concentration that would be inadequate during rapid bleeding or limited cardiopulmonary reserve. (who.int)\n\nRed-cell transfusion also provides temporary support when bone marrow cannot produce sufficient erythrocytes. Examples include disease-related marrow failure and suppression associated with chemotherapy; transfusion improves oxygen-carrying capacity without correcting the underlying production defect. Breathlessness, impaired cardiovascular compensation, anemia severity, and ongoing blood loss influence the expected benefit. (professionaleducation.blood.ca) In sickle cell disease, transfusion has additional disease-specific purposes, including treatment of severe complications and scheduled stroke prevention in selected patients. These indications differ from simply correcting a low hemoglobin measurement: chronic anemia or an uncomplicated painful episode does not, by itself, establish a need for transfusion. Exchange techniques and long-term component selection involve additional considerations. (hematology.org)\n\nPlatelet transfusion is therapeutic when used to control bleeding associated with insufficient or dysfunctional platelets, and prophylactic when used to prevent bleeding before it occurs. A defined prophylactic setting is hospitalized patients with treatment-induced hypoproliferative thrombocytopenia, in whom guidance includes a platelet count below \\(10 \\times 10^{9}/\\mathrm{L}\\). This is not a universal platelet threshold: bleeding site, additional risk factors, and planned procedures alter assessment. The mechanism of thrombocytopenia also matters. Transfused platelets may be rapidly destroyed in immune thrombocytopenia, where their use is generally reserved for critical bleeding; they are generally avoided in thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia because of potential thrombotic harm. (professionaleducation.blood.ca)\n\nPlasma supplies multiple coagulation factors when clinically important bleeding, or a relevant procedural bleeding risk, accompanies factor deficiency and more specific therapy is unavailable. Examples include massive hemorrhage with coagulopathy, severe liver disease, and disseminated intravascular coagulation. Plasma is not simply a volume-replacement fluid. Cryoprecipitate supplies fibrinogen in bleeding accompanied by acquired fibrinogen deficiency; manufactured fibrinogen concentrate is a distinct replacement option. For hemophilia and other defined factor deficiencies, specific concentrates have displaced many historical uses of plasma or cryoprecipitate where such products are available. (professionaleducation.blood.ca)\n\nRestrictive and liberal red-cell strategies describe different hemoglobin thresholds for considering transfusion, not different levels of clinical monitoring. The 2023 AABB international guidelines evaluated 45 adult randomized trials involving 20,599 participants, generally comparing restrictive thresholds of 7–8 g/dL with liberal thresholds of 9–10 g/dL. For most studied populations, restrictive strategies did not adversely affect patient-important outcomes. The guidelines supported considering transfusion below 7 g/dL in hemodynamically stable hospitalized adults, with different trial-based thresholds for certain surgical and cardiovascular groups. These findings do not establish a single threshold for active hemorrhage or every underlying disease. (doi.org) In August 2025, separate AABB guidance conditionally favored a liberal strategy for hospitalized patients with acute myocardial infarction and hemoglobin below 10 g/dL, while explicitly retaining assessment of clinical context. (aabb.org)"
    },
    {
      "heading": "Donation, Collection, and Infectious-Disease Screening",
      "text": "Blood services recruit and retain donors through public education and organized donation programmes; the World Health Organization (WHO) promotes regular, voluntary, unpaid donation. Before collection, eligibility assessment combines a health-history questionnaire, confidential discussion, and physical checks. Questions address illnesses, medicines, previous procedures, travel or residence in areas with particular infections, and potential infectious exposures. Age, weight, donation intervals, and deferral rules vary among jurisdictions. Donors receive information about collection and testing and provide informed consent. Selection protects both recipients and donors: haemoglobin screening identifies donors below the permitted threshold, while limits on collection volume and frequency reduce donation-related harm. (who.int)\n\nWhole-blood collection removes blood into a sterile, single-use collection system containing anticoagulant; components may subsequently be separated. Canadian Blood Services describes a typical donation as approximately 450 mL. In apheresis, an automated separator collects selected components, such as platelets or plasma, while returning the uncollected constituents to the donor. The permitted yield depends on donor characteristics and the component collected. Donor protection also extends beyond the collection visit: each whole-blood donation removes approximately 225–250 mg of iron, and repeated donation can produce iron deficiency even before anaemia develops. A satisfactory haemoglobin result therefore does not establish that iron stores are adequate. (blood.ca)\n\nWHO recommends screening every donation before use for HIV, hepatitis B, hepatitis C, and syphilis. Serological assays detect antibodies against an infectious agent or its antigens, rather than necessarily detecting the organism itself. Examples include antibodies to HIV and hepatitis C virus, hepatitis B surface antigen, and antibodies used in syphilis screening. Nucleic-acid testing (NAT) instead detects pathogen genetic material—for example, HIV or hepatitis C viral RNA and hepatitis B viral DNA. Depending on the programme, NAT uses individual samples or pools that undergo further testing when reactive. Screening-reactive donations are excluded according to the applicable testing algorithm; confirmatory investigations inform donor notification and distinguish confirmed infection from false reactivity. (who.int)\n\nThe window period is the interval between acquisition of an infection and its detectability by a particular assay. A donor may appear healthy and carry transmissible infection while screening remains negative. NAT reduces reliance on the later appearance of antibodies, but does not eliminate an early interval when pathogen concentrations remain below detection limits. Window periods differ by organism and assay, so no single duration describes all screening tests. Donor selection and laboratory testing consequently address overlapping but non-identical risks; neither replaces the other. (blood.ca)\n\nBacterial contamination requires additional controls, particularly for platelets stored at room temperature. Skin disinfection and diversion of the first collected blood into a separate pouch reduce entry of skin-associated bacteria into the main collection. Platelet safety programmes may also use bacterial culture, rapid detection tests, or pathogen reduction. These measures do not guarantee sterility: in a December 22, 2022 communication, the US Food and Drug Administration described seven septic reactions associated with six donations investigated since 2018, including components subjected to bacterial testing or pathogen reduction. (professionaleducation.blood.ca)\n\nAdditional infectious precautions reflect regional exposure patterns. Travel and residence histories help identify malaria risk; deferral and testing policies differ between blood services. Canadian screening also illustrates targeted testing for Trypanosoma cruzi, the cause of Chagas disease, and geographically responsive West Nile virus testing. These measures are distinct from pathogen reduction, which treats the collected component—for example, by damaging microbial nucleic acids with a photosensitizing agent and ultraviolet light. Its effectiveness depends on the pathogen and product; it is an additional manufacturing safeguard, not evidence that every infectious threat has been removed. (who.int)"
    },
    {
      "heading": "Component Preparation, Modification, and Storage",
      "text": "Whole blood is processed in interconnected bags that permit component transfer within a closed system. Centrifugation separates a dense red-cell layer, an intermediate buffy coat containing platelets and leukocytes, and plasma. Red cells are filtered and suspended in an additive solution; buffy coats can be pooled and centrifuged again to recover platelets. Citrate-phosphate-dextrose (CPD) provides anticoagulation during collection, while red-cell additives supply nutrients and improve preservation. Canadian Blood Services’ February 2026 circular describes SAGM—saline, adenine, glucose, and mannitol—as the additive for its standard leukoreduced red-cell component. Plasma separated from whole blood is frozen; cryoprecipitate is subsequently prepared by slowly thawing frozen plasma, centrifuging out the insoluble, fibrinogen-rich fraction, and refreezing it. (professionaleducation.blood.ca)\n\nStorage conditions preserve different biological properties and are not interchangeable. Canadian SAGM red cells are stored at 1–6°C for up to 42 days. Conventional platelets require 20–24°C with continuous gentle agitation; Canadian platelet components have a seven-day shelf life. For the untreated frozen-plasma products described in the Canadian circular, storage is at −18°C or colder for up to 12 months. After thawing, those plasma products have a refrigerated expiry of 120 hours, whereas thawed cryoprecipitate is stored at 20–24°C and expires after four hours. These are product- and jurisdiction-specific examples, not universal limits: the licensed component label governs expiry, including any changes following processing or opening of the system. (blood.ca)\n\nLeukoreduction, washing, and irradiation have distinct targets. Pre-storage leukoreduction removes white cells by filtration, reducing exposure to leukocyte-associated infectious agents such as cytomegalovirus, but does not reliably prevent transfusion-associated graft-versus-host disease. Washing removes plasma and soluble substances, including antibodies, plasma proteins, potassium, and accumulated metabolites, by repeated rinsing and supernatant removal. It is used for selected recipients with severe or recurrent reactions, but causes cell loss and can shorten expiry substantially. Canadian Blood Services introduced closed-system automated red-cell washing in 2013, permitting seven days of post-wash storage; open-system washing generally limits expiry to 24 hours. (professionaleducation.blood.ca)\n\nIrradiation instead damages the DNA of residual donor T lymphocytes, preventing their proliferation and consequent attack on recipient tissues. Gamma-ray or X-ray systems deliver a controlled dose; Canadian guidance specifies 25 Gy at the pack’s centre, with other regions receiving 15–50 Gy. Irradiation does not remove plasma proteins and is not a substitute for infectious-disease screening. It also increases red-cell membrane damage, potassium leakage, and hemolysis, necessitating revised expiry limits. Under the cited Canadian standard, irradiated red cells expire no later than 14 days after irradiation and 28 days after collection, whichever comes first. (professionaleducation.blood.ca)\n\nPathogen reduction targets contaminating organisms rather than simply removing leukocytes or plasma. One platelet-processing method adds amotosalen, a psoralen compound, followed by ultraviolet A illumination at 320–400 nm. Activated amotosalen crosslinks nucleic acids, impairing replication of susceptible viruses, bacteria, parasites, and donor leukocytes; an adsorption step removes residual compound and photoproducts. These treated platelets do not require additional irradiation. Treatment nevertheless does not sterilize every possible contamination: efficacy varies with the organism, initial burden, and processing conditions, and some agents, including prions, resist the method. Donor screening and donation testing therefore remain separate safeguards. (professionaleducation.blood.ca)\n\nStorage progressively alters component quality. In red cells, potassium accumulates outside the cells, membrane-derived vesicles increase, and hemolysis releases hemoglobin into the supernatant; irradiation can accelerate these changes. Manufacturing quality control tests defined samples for hemoglobin, hematocrit, residual leukocytes, hemolysis, volume, and sterility; platelet testing includes yield and pH, while plasma and cryoprecipitate testing includes factor VIII and fibrinogen respectively. Individual-unit checks include label and expiry verification, bag integrity, visual appearance, and acceptable temperature history. Alarmed, continuously monitored refrigerators and freezers, validated transport containers, and documented dispatch and receipt preserve the cold chain; an intact bag alone does not establish that a component remains suitable for release. (blood.ca)"
    },
    {
      "heading": "Blood Groups and Compatibility Testing",
      "text": "The ABO blood group system distinguishes red cells bearing A antigen, B antigen, both antigens (AB), or neither (O). From early childhood, individuals ordinarily possess antibodies against the ABO antigens absent from their own cells: group A plasma contains anti-B, group B contains anti-A, group O contains both, and group AB contains neither. These antibodies are predominantly IgM, although IgG forms also occur. Incompatible donor red cells can therefore encounter pre-existing antibodies immediately; antibody binding and activation of the complement system can produce rapid hemolysis. For example, a group O recipient’s anti-A attacks transfused group A cells. (lifeblood.com.au)\n\nThe Rh blood group system includes D, C, c, E, and e antigens; “positive” and “negative” in routine blood-group descriptions refer specifically to D. Unlike the usual ABO antibodies, anti-D generally follows exposure to D-positive red cells through transfusion or pregnancy. It can cause hemolytic transfusion reactions and, because it is usually IgG and crosses the placenta, hemolytic disease of the fetus and newborn. Kell, Kidd, and Duffy are additional clinically significant systems: antibodies directed against their antigens can accelerate destruction of transfused red cells. Consequently, matching ABO and RhD alone does not establish compatibility for every recipient. (lifeblood.com.au)\n\nTesting begins with unequivocal patient identification and a correctly attributed specimen. Identification details are checked against the request and identification band; tubes are labeled immediately after collection beside the patient, rather than in advance. Labels include approved patient identifiers and collection details. Previous blood-group results, transfusions, and obstetric history are reviewed. Sample validity reflects the possibility of newly developing antibodies: Australian guidance updated in January 2026 normally specifies 72 hours following transfusion or pregnancy within the preceding three months, with longer validity possible in defined circumstances. This is a jurisdiction-specific rule, not a universal biological cutoff. (prod2.lifeblood.com.au)\n\nForward ABO grouping tests the patient’s red cells with anti-A and anti-B reagents; reverse grouping tests the patient’s plasma against known A and B cells. The results must agree before the ABO assignment is accepted. Reverse grouping is not required in infants younger than four months, whose detected antibodies may be maternal. RhD typing tests red cells with anti-D. Separately, antibody screening exposes patient plasma to selected group O reagent cells expressing clinically important non-ABO antigens. A positive screen prompts antibody identification using a larger panel with known antigen profiles; complex investigations may require a reference laboratory and several days. (professionaleducation.blood.ca)\n\nCrossmatching assesses compatibility with a particular donor unit. Serological methods physically test recipient plasma against donor red cells: immediate-spin testing primarily checks ABO compatibility, whereas indirect antiglobulin crossmatching detects clinically significant IgG reactivity. Electronic crossmatching uses a validated laboratory information system without physically mixing samples and requires eligibility criteria, including no current or historical clinically significant antibodies. An antibody history remains relevant even when the current screen is negative; corresponding antigen-negative units are selected and tested by an antiglobulin crossmatch. Thus, a previously documented anti-K affects selection by requiring K-negative red cells. (prod2.lifeblood.com.au)\n\nRed-cell and plasma compatibility operate in opposite directions. Red-cell selection avoids donor antigens targeted by recipient antibodies; plasma selection avoids donor antibodies targeting recipient red cells. A group A recipient can receive A or O red cells on ABO grounds, but A or AB plasma. AB plasma lacks anti-A and anti-B, whereas O red cells lack A and B antigens. “Universal donor” is therefore component-specific: O RhD-negative red cells still carry other potentially incompatible antigens. Emergency release is a separate, documented departure from completed testing: group O uncrossmatched red cells may be issued before typing, or group-specific uncrossmatched cells after ABO/RhD determination, with compatibility testing continuing so that appropriately matched units can subsequently replace them. (lifeblood.com.au)"
    },
    {
      "heading": "Administration and Clinical Monitoring",
      "text": "The clinical workflow begins with a documented indication and an authorized order specifying the component, quantity or volume, intended timing and duration, and any special processing requirements. Laboratory compatibility testing, component issue, transport, bedside administration, and monitoring form a connected safety process: the World Health Organization described this sequence explicitly in its 2010 aide-mémoire on clinical transfusion safety. Patient identification must remain consistent across the request, specimen, laboratory record, and component label. Delivery to the clinical area is coordinated with readiness to transfuse, avoiding unnecessary time outside controlled storage. Documentation of informed consent accompanies preparation according to the applicable institutional framework. (who.int)\n\nImmediately before administration, trained staff verify the recipient and component at the bedside rather than relying solely on earlier laboratory checks. Verification matches the patient’s identifiers with the identification band, prescription, and compatibility label, and checks the component type, donation identification number, compatibility, expiry, prescribed modifications, and container integrity. For example, the Royal Children’s Hospital Melbourne requires two clinicians to perform independent bedside checks; its procedure also incorporates barcode scanning and electronic documentation. Such arrangements are institution-specific, but their purpose is to prevent a correctly tested component from reaching the wrong recipient. A discrepancy or abnormal component appearance prevents administration pending resolution by the transfusion service. (rch.org.au)\n\nComponents enter the circulation through peripheral intravenous catheters or central venous access devices selected for the required flow and the patient’s vascular access. Standard blood administration sets contain filters with pores typically measuring 170–260 micrometres, which retain clots and particulate debris. These filters do not replace component processing or compatibility testing. Infusion pumps, pressure devices, and rapid infusers must be suitable for blood and operated under institutional procedures. Blood warmers have selected uses, particularly rapid administration of refrigerated components during surgery or trauma care, when heat loss may be substantial; warming is not an automatic requirement for every transfusion. Equipment selection and use follow product instructions and local policy. (professionaleducation.blood.ca)\n\nBaseline observations establish a comparison against which subsequent changes can be interpreted. Temperature, pulse, respiratory rate, and blood pressure are recorded, together with relevant pre-existing symptoms, such as a rash. Australian Red Cross Lifeblood guidance, updated in December 2025, specifies close observation during the first 15 minutes of each pack, observations at least hourly thereafter, and vital-sign recording before transfusion, at 15 minutes, and on completion. More frequent assessment depends on clinical condition and local policy. New fever, chills, rash, breathing difficulty, falling oxygen saturation, or unexpected blood-pressure or pulse changes prompt assessment for a reaction. Monitoring extends beyond completion because some reactions develop later. (lifeblood.com.au)\n\nThe administration record links each donation number to the recipient and records timing, volume administered, observations, and adverse events. Clinical and laboratory reassessment evaluates whether the intended benefit occurred, using measures appropriate to the component and indication. When a reaction is suspected, clinical staff interrupt transfusion, assess airway, breathing, and circulation, and notify the responsible clinician and transfusion laboratory. Investigation includes repeated identity checks and, where indicated, examination of the returned pack and tubing and testing of fresh patient samples. Suspected hemolysis may require repeat grouping, a direct antiglobulin test, and biochemical markers of red-cell destruction; suspected sepsis may require cultures of patient blood and the component. Findings and their implications for subsequent transfusions are documented in the medical record. (professionaleducation.blood.ca)"
    },
    {
      "heading": "Specialized Transfusion Settings and Techniques",
      "text": "Massive-hemorrhage protocols coordinate the clinical team, transfusion laboratory, and transport services so that red cells, plasma, and platelets reach a rapidly bleeding patient while the source of bleeding is controlled. Predetermined component packs support initial resuscitation before laboratory results are available; their composition depends on the institution and bleeding setting, rather than a ratio applicable to every patient. Subsequent replacement is increasingly directed by repeated blood counts, coagulation times, fibrinogen concentration, blood gases, lactate, and ionized calcium. Viscoelastic testing, such as thromboelastography, can additionally assess clot formation, strength, and breakdown in whole blood. These measurements distinguish oxygen-carrying requirements from platelet or coagulation-factor deficiencies during rapidly changing blood loss. (professionaleducation.blood.ca)\n\nFetal and neonatal transfusion must account for maternal antibodies, which cross the placenta and may destroy fetal red cells. Intrauterine transfusion supplies compatible red cells before birth; component selection incorporates maternal antibody findings, and cellular components are irradiated for this setting. After birth, neonatal compatibility testing may use a maternal or infant sample, and donor cells must be compatible with both the infant’s blood group and circulating maternal antibodies. Pediatric transfusions use weight-based volumes and small aliquots rather than automatically administering an adult unit. Repeated aliquots prepared from one donation can limit exposure to different donors. Canadian Blood Services describes neonatal red-cell volumes of approximately 10–20 mL/kg, with the actual volume dependent on the component and clinical circumstances. (clinicalguidelines.scot.nhs.uk)\n\nNeonatal exchange transfusion differs from a small-volume “top-up”: successive portions of the infant’s blood are removed and replaced with compatible donor blood. In severe neonatal hyperbilirubinemia, this reduces circulating bilirubin; in antibody-mediated disease it also removes maternal antibodies and affected red cells while correcting anemia. Selection depends on gestational age, bilirubin measurements, and response to phototherapy, not simply on a low hemoglobin concentration. A double-volume exchange removes more maternal antibody than a single-volume procedure but does not eliminate it completely. (clinicalguidelines.scot.nhs.uk)\n\nRepeated transfusion in sickle cell disease and other hemoglobinopathies requires planning beyond ABO and RhD compatibility. Simple transfusion adds donor red cells, increasing oxygen-carrying capacity but also total red-cell mass and iron burden. Red-cell exchange removes recipient cells while replacing them with donor cells, lowering the proportion of sickle hemoglobin without an equivalent rise in hematocrit; automated exchange can reduce net iron accumulation compared with repeated simple transfusion. The American Society of Hematology’s 2020 guidelines recommend early extended antigen profiling and prophylactic matching for Rh C/c, E/e, and Kell antigens in sickle cell disease. Further matching for Kidd, Duffy, and S/s antigens may provide additional protection against alloimmunization. (pmc.ncbi.nlm.nih.gov)\n\nSpecialized support for hematopoietic stem-cell transplantation and selected immunodeficiencies includes irradiated cellular components, which prevent donor T lymphocytes from proliferating. Leukoreduction alone does not replace irradiation for this purpose, and solid-organ transplantation alone is not generally an irradiation indication. Antigen-negative red cells are selected when clinically significant antibodies are present; HLA-selected platelets may support patients with immune-mediated platelet refractoriness. CMV-seronegative components have selected uses, but policies differ: Canadian guidance considers leukoreduced and CMV-seronegative components equivalent for most indications, with an exception for intrauterine transfusion. (professionaleducation.blood.ca)\n\nAutologous techniques differ principally in when blood is collected. Perioperative cell salvage recovers shed blood, separates and washes the red cells, and returns them to the same patient. The resulting suspension does not replace the platelets and coagulation factors lost during bleeding. Preoperative autologous donation instead collects and stores blood before elective surgery. Its limitations include donation-induced anemia, unused units, and persistent risks of bacterial contamination or identification errors. Canadian Blood Services therefore restricts this approach largely to exceptional compatibility problems, such as rare phenotypes or multiple antibodies that make suitable donor blood difficult to obtain. (wisdom.nhs.wales)"
    },
    {
      "heading": "Adverse Effects and Their Mechanisms",
      "text": "Transfusion reactions are classified by timing—acute, generally within 24 hours, or delayed—and by immune, infectious, or other nonimmune mechanisms. Acute immune hemolysis occurs when recipient antibodies attack transfused red cells: ABO incompatibility can activate the complement system, causing intravascular destruction, hypotension, kidney injury, and disseminated intravascular coagulation. Delayed hemolytic reactions usually appear between 24 hours and 28 days after transfusion. Previous transfusion or pregnancy may have generated antibodies that subsequently fell below screening detection; re-exposure provokes a secondary immune response. Antibodies against Kidd, Duffy, Kell, or Rh antigens can cause predominantly extravascular red-cell destruction, producing jaundice and an unexpectedly low or falling hemoglobin concentration. (lifeblood.com.au)\n\nFebrile nonhemolytic reactions arise from inflammatory cytokines in the component or recipient antibodies reacting with donor leukocytes, producing fever and sometimes rigors without immune red-cell destruction. Fever alone does not establish this diagnosis because hemolysis and bacterial sepsis can present similarly. Allergic reactions commonly cause itching and urticaria; proposed triggers include donor plasma proteins and other allergens, although mechanisms are not always identifiable. Anaphylaxis involves systemic manifestations such as airway swelling, bronchospasm, and hypotension. Anti-IgA antibodies in an IgA-deficient recipient explain only a minority of cases; IgA deficiency alone does not establish the cause of a severe reaction. (professionaleducation.blood.ca)\n\nTransfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI) both produce hypoxemia and pulmonary edema, but through different mechanisms. TACO is predominantly hydrostatic: transfused volume and infusion rate exceed cardiovascular capacity, increasing pulmonary vascular pressure. Cardiac or renal dysfunction increases susceptibility. The 2018 international surveillance definition permits onset during or up to 12 hours after transfusion. TRALI develops during or within six hours and involves increased pulmonary capillary permeability rather than predominantly circulatory overload. In a widely used mechanistic model, recipient inflammation primes pulmonary neutrophils, which donor anti-HLA or anti-HNA antibodies, or other biological mediators, subsequently activate. Endothelial injury then permits fluid leakage. Donor antibodies are not demonstrable in every case, and hydrostatic and permeability-related edema can coexist. (professionaleducation.blood.ca)\n\nTransfusion-transmitted infection is distinct from these noninfectious reactions. Residual viral risk persists when an infectious donation escapes detection, including during the interval before laboratory markers become detectable. Bacterial contamination can instead cause rapidly developing fever, rigors, hypotension, and sepsis. Conventional platelet storage at 20–24°C permits bacterial multiplication more readily than refrigerated red-cell storage. Contamination can originate from donor skin, transient donor bacteremia, or processing. An Australian surveillance study covering 2016–2022 documented five confirmed or highly probable bacterial transmissions: four involving platelets and one involving red cells. Such dated, component-specific observations are not universal estimates of infection risk. (professionaleducation.blood.ca)\n\nAlloimmunization is the formation of antibodies against donor antigens absent from the recipient. Besides complicating subsequent red-cell transfusions, antibodies against HLA class I or platelet-specific antigens can cause platelet refractoriness—repeatedly inadequate post-transfusion platelet increments. However, bleeding, sepsis, and other nonimmune causes account for most refractory responses. Post-transfusion purpura is a separate, rare syndrome of profound thrombocytopenia, typically seven to ten days after transfusion, associated with platelet alloantibodies and destruction of the recipient’s own platelets as well as donor platelets. In transfusion-associated graft-versus-host disease, viable donor T lymphocytes engraft and attack recipient tissues, causing fever, rash, diarrhea, liver abnormalities, and marrow aplasia. Immunodeficiency and close donor–recipient HLA similarity increase susceptibility. (prod2.lifeblood.com.au)\n\nCumulative and large-volume complications need not involve immune recognition. Each red-cell unit contains approximately 200–250 mg of iron; repeated transfusions can deposit iron in the liver, heart, and endocrine organs, impairing their function. Rapid infusion of cold components contributes to hypothermia. Citrate anticoagulant binds ionized calcium, potentially causing hypocalcemia when delivery exceeds metabolic clearance. Potassium accumulating outside stored red cells can produce hyperkalemia during rapid transfusion, particularly in vulnerable recipients. These temperature and electrolyte disturbances can impair coagulation or cardiac function and occur alongside the physiological consequences of the underlying hemorrhage. (professionaleducation.blood.ca)"
    },
    {
      "heading": "Patient Blood Management and Alternatives",
      "text": "Patient blood management (PBM) coordinates the recognition and treatment of anemia, reduction of blood loss, and management of coagulation disorders to improve patient outcomes. It is not synonymous with avoiding transfusion: clinically indicated blood components remain part of care. The World Health Organization’s 2021 policy brief explicitly included surgical and nonsurgical patients, treating iron deficiency, anemia, bleeding, and coagulopathy as health problems in their own right rather than merely reasons to order blood. PBM therefore extends from assessment before elective procedures to management during hospitalization and recovery, linking correction of underlying disease with preservation of the patient’s own blood. (who.int)\n\nInvestigation distinguishes iron-deficiency anemia from anemia caused by inflammation, kidney disease, nutritional deficiencies, or impaired marrow function. A complete blood count establishes hemoglobin concentration and red-cell indices; iron studies, including ferritin and transferrin saturation, help identify insufficient iron stores or restricted iron availability. The 2023 International Consensus Conference on Anemia Management in Surgical Patients identified ferritin below 30 ng/mL and/or transferrin saturation below 20% as important criteria for iron deficiency; because ferritin rises during inflammation, a value below 100 ng/mL may indicate deficiency in inflammatory states. Investigation also addresses the cause of deficiency, such as continuing blood loss, rather than assuming that replacement alone resolves the disorder. (pmc.ncbi.nlm.nih.gov)\n\nOral and intravenous iron supply material for hemoglobin synthesis and endogenous red-cell production, whereas transfused donor cells provide an immediate increase in circulating oxygen-carrying capacity. Intravenous iron has a role when oral treatment cannot be tolerated or absorbed, or when the interval before surgery is too short for oral therapy to be effective. Neither route reproduces the immediate physiological effect of red-cell transfusion, and transfusion does not remove the underlying cause of anemia. Treatment is therefore directed by etiology: iron replacement addresses iron deficiency, while other nutritional deficiencies, renal disease, or hematological disorders require different approaches. (pmc.ncbi.nlm.nih.gov)\n\nBlood conservation reduces both overt bleeding and cumulative losses from care. WHO implementation guidance includes smaller-volume laboratory sampling tubes and patient-specific surgical planning to limit the extent and duration of procedures. Avoiding unnecessary repeat tests preserves circulating red cells, while surgical hemostasis controls bleeding at its source. Tranexamic acid acts differently: as an antifibrinolytic, it limits breakdown of fibrin clots rather than replacing lost cells. In the CRASH-2 collaborators’ 2010 randomized trial of 20,211 adults with, or at risk of, significant traumatic bleeding, all-cause mortality was 14.5% with tranexamic acid and 16.0% with placebo. This result concerns a defined trauma population, not a universal substitute for transfusion or mechanical control of hemorrhage. (iris.who.int)\n\nOther alternatives replace particular functions rather than blood as a whole. Isotonic crystalloids, such as saline or Ringer’s lactate, expand circulating fluid volume but contain no hemoglobin-bearing red cells and therefore do not restore oxygen-carrying capacity. Targeted hemostatic treatments address specific defects: vitamin K supports correction of vitamin-K-dependent factor deficiency, prothrombin complex concentrates replace selected coagulation factors, and specific factor concentrates treat corresponding deficiencies. Canadian Blood Services distinguishes these uses from plasma transfusion and states that neither plasma nor red cells are indicated solely for volume replacement. Fluids, anemia treatments, antifibrinolytics, and factor replacement consequently have different physiological targets and times to effect; none is an interchangeable replacement for all blood components. (professionaleducation.blood.ca)"
    },
    {
      "heading": "Blood Services, Consent, and Hemovigilance",
      "text": "National blood services coordinate donor recruitment, collection, testing, processing, storage, and distribution through integrated networks; hospital transfusion laboratories perform compatibility testing, select and issue components, and maintain local stocks. The World Health Organization recommends national coordination, although this does not require a single collecting organization. Regulatory authorization and professional accreditation serve different functions. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency authorizes blood establishments and inspects them at least every two years; hospital blood banks submit annual compliance reports and undergo risk-based inspection. AABB accreditation assesses conformity with professional standards through self-assessment and on-site assessment. (who.int)\n\nTraceability connects each donor and donation to the resulting components, their distribution, and their final recipients or other disposition. It must therefore record more than delivery to a hospital: an issued unit may be transfused, returned, or discarded. The United Kingdom’s 2006 amendments to its Blood Safety and Quality Regulations specify records identifying the donor, donation, individual component, receiving facility, recipient, and date of transfusion or disposal. These links allow investigations to proceed from donor to recipient and in the reverse direction, including when several components originated from one donation. (legislation.gov.uk)\n\nAvailability differs substantially between health systems. WHO’s Global status report on blood safety and availability 2025, published in 2026, uses data through 2023. Its June 2026 fact sheet reports approximately 120.4 million donations worldwide, with 36% collected in high-income countries containing 15% of the world’s population. Donation rates per 1,000 population were 28.9 in high-income countries, 18.2 in upper-middle-income countries, 8.5 in lower-middle-income countries, and 4.5 in low-income countries. Component separation also differed: 98% of collected blood was separated in high-income countries, compared with 52% in low-income countries. These are collection and processing indicators, not direct measures of whether an individual patient receives appropriate treatment on time; WHO separately identifies timely access as an unresolved problem. (who.int)\n\nInformed consent involves discussion of the proposed component, expected benefit, material risks, alternatives, and the consequences of declining treatment, with the discussion and decision recorded. Canadian Blood Services’ guidance emphasizes understandable information and time for questions. The United Kingdom’s SaBTO guidelines, approved on June 4, 2025, likewise treat consent as a documented decision-making process rather than merely a signature. They address recording patients’ preferences, including partial refusal of components, and recognize withdrawal of consent. Emergency and pediatric arrangements are jurisdiction-specific: SaBTO describes emergency treatment of a child when delay for parental consent would place the child at risk, while explicitly noting legal differences among UK nations. (professionaleducation.blood.ca)\n\nHemovigilance covers monitoring, reporting, investigation, and analysis of adverse events throughout donation, processing, and transfusion, followed by preventive action. It includes errors intercepted before harm occurs: the UK Serious Hazards of Transfusion scheme defines a near miss as an error that could have caused incorrect blood grouping or component transfusion but was detected before transfusion. Such reports expose weaknesses in identification and laboratory processes without requiring a patient injury first. Infection investigations distinguish donor-initiated lookback, which identifies recipients of potentially infectious earlier donations, from recipient-initiated traceback, which investigates whether transfusion could explain a newly identified infection. Findings support changes in procedures and subsequent quality monitoring. (who.int)\n\nInventory management balances shortages against expiry-related wastage through stock targets, demand monitoring, redistribution, and coordinated emergency plans. Canada’s National Advisory Committee maintains a national shortage plan and resources for simulated shortage exercises. Rare-donor resources address compatibility problems that aggregate stock totals cannot reveal: Canadian Blood Services combines targeted donor recruitment, frozen rare-unit storage, and cooperation with the International Rare Donor Panel to locate compatible blood when domestic units or immediately available donors cannot meet a patient’s needs. These activities form a specialized part of the blood supply chain, alongside routine collection and hospital distribution. (profedu.blood.ca)"
    },
    {
      "heading": "Research and Developing Technologies",
      "text": "Randomized controlled trials evaluate transfusion strategies through clinical outcomes rather than assuming that a higher hemoglobin concentration necessarily improves recovery. The 2023 Myocardial Ischemia and Transfusion (MINT) trial assigned 3,504 patients with myocardial infarction and anemia to restrictive or liberal red-cell transfusion strategies, using hemoglobin thresholds of approximately 7–8 and 10 g/dL, respectively. Death or recurrent myocardial infarction within 30 days occurred in 16.9% and 14.5%, respectively; the estimated risk ratio was 1.15, with a 95% confidence interval of 0.99–1.34. The primary comparison did not establish statistically significant superiority of the liberal strategy, but it did not exclude clinically important harm from restriction. Hemoglobin changes documented the physiological separation between groups; the clinical endpoint tested whether that separation benefited patients. (doi.org)\n\nTrials also test whether component characteristics affect outcomes. In the 2017 TRANSFUSE trial, 4,919 critically ill adults were included in the primary analysis comparing the freshest available compatible red cells with standard-issue cells. Mean storage durations were 11.8 and 22.4 days, while 90-day mortality was 24.8% and 24.1%, respectively, without a significant difference. This comparison illustrates why laboratory evidence of storage-related deterioration cannot, by itself, establish that preferentially issuing fresher blood improves survival. Its findings concern the populations and storage distributions studied, rather than every possible storage duration or recipient group. (nejm.org)\n\nLaboratory-grown red blood cells are being evaluated in RESTORE, a phase I, randomized, single-blind crossover clinical trial led by Cédric Ghevaert and Rebecca Cardigan. Adult donor blood provides CD34-positive stem and progenitor cells, which are isolated and cultured to produce red cells. Healthy volunteers receive approximately 5–10 mL of manufactured cells and a comparable dose of conventional red cells from the same donor, in randomized order, at least four months apart. Tracer labeling permits measurement of post-transfusion recovery and circulating survival. The hypothesis is that a population of newly produced cells survives longer than donated blood containing cells of different ages. These measurements do not themselves demonstrate fewer transfusions or reduced iron accumulation in chronically transfused patients; those remain anticipated benefits requiring further clinical evaluation, not established outcomes or routine availability. (nhsbt.nhs.uk)\n\nTranslation requires substantially greater manufacturing yield, reproducibility, and affordability. Research at Bristol examines how immature cultured cells acquire the mature biconcave form, how to improve cell isolation, and how to reproduce aspects of bone-marrow production more efficiently. Immortalized erythroid precursor lines offer another route to repeated production, distinct from RESTORE’s donor-derived starting material. NHS Blood and Transplant identifies culture cost, scale-up, clinical-grade manufacture, and further testing as barriers. Compatibility also remains a separate problem: experimental gene-edited precursor lines lacking selected Rh, Kell, Duffy, and other blood-group targets can produce reticulocytes, but laboratory characterization does not establish their suitability for transfusion into humans. (bristol.ac.uk)\n\nResearch on platelet processing combines infection control with assessment of preserved hemostatic function. The INTERCEPT system uses amotosalen and ultraviolet A light to cross-link nucleic acids, preventing replication of susceptible pathogens and contaminating leukocytes. Subsequent adsorption reduces residual amotosalen and photoproducts. In the United States, FDA authorization specifies particular apheresis platelet preparations and processing configurations; it is not blanket approval of all pathogen-reduction methods or blood components. The product labeling also identifies resistant organisms and explicitly does not claim elimination of every pathogen. (fda.gov)\n\nClinical evidence is likewise preparation-specific. The 2018 EFFIPAP trial evaluated 790 patients with thrombocytopenia and malignant hematologic disease. Grade 2 or greater bleeding occurred in 47.9% receiving pathogen-reduced platelets in additive solution, 43.5% receiving untreated platelets in plasma, and 45.3% receiving untreated platelets in additive solution. Under the prespecified noninferiority margin, pathogen-reduced platelets met the criterion against untreated platelets in additive solution but not against those in plasma. The differing comparisons show why processing technology, suspension medium, and the chosen clinical endpoint must be considered together rather than treating all platelet products as equivalent. (pubmed.ncbi.nlm.nih.gov)"
    }
  ],
  "links": [
    "erythrocyte",
    "anemia",
    "surgery",
    "cancer",
    "abo-blood-group-system",
    "hemoglobin",
    "oxygen",
    "platelet",
    "leukocyte",
    "neutrophil",
    "world-war-i",
    "world-war-ii",
    "hiv-aids",
    "hepatitis-c",
    "bone-marrow",
    "chemotherapy",
    "sickle-cell-disease",
    "hemophilia",
    "randomized-controlled-trial",
    "world-health-organization",
    "informed-consent",
    "hepatitis-b",
    "syphilis",
    "antibody",
    "antigen",
    "bacteria",
    "malaria",
    "protein",
    "t-cell",
    "hemolysis",
    "virus",
    "complement-system",
    "pregnancy",
    "rash",
    "fever",
    "shortness-of-breath",
    "sepsis",
    "complete-blood-count",
    "hematopoietic-stem-cell-transplantation",
    "cytokine",
    "anaphylaxis",
    "edema",
    "electrolyte",
    "iron-deficiency-anemia",
    "ferritin",
    "inflammation",
    "hematopoiesis",
    "health-system",
    "supply-chain",
    "clinical-trial",
    "pathogen"
  ],
  "sources": [
    {
      "title": "Blood components",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/blood-components"
    },
    {
      "title": "Plasma, Platelets and Whole Blood | Red Cross Blood Services",
      "url": "https://www.redcrossblood.org/donate-blood/how-to-donate/types-of-blood-donations/blood-components.html"
    },
    {
      "title": "Preoperative autologous donation",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/preoperative-autologous-donation"
    },
    {
      "title": "Blood Basics - Hematology.org",
      "url": "https://www.hematology.org/education/%20patients/blood-basics"
    },
    {
      "title": "Cryoprecipitated AHF (Cryo) | American Red Cross",
      "url": "https://www.redcrossblood.org/biomedical-services/blood-products-and-services/cryoprecipitate.html"
    },
    {
      "title": "Granulocyte transfusion therapy",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/granulocyte-transfusion-therapy"
    },
    {
      "title": "Transfusion Medicine History",
      "url": "https://www.aabb.org/blood-biotherapies/blood/transfusion-medicine/transfusion-medicine-resources/transfusion-medicine-history"
    },
    {
      "title": "History Of Blood Transfusions 1628 To Now",
      "url": "https://www.redcrossblood.org/donate-blood/blood-donation-process/what-happens-to-donated-blood/blood-transfusions/history-blood-transfusion.html"
    },
    {
      "title": "A history of donation, transfusion and transplantation",
      "url": "https://www.nhsbt.nhs.uk/who-we-are/a-history-of-donation-transfusion-and-transplantation/"
    },
    {
      "title": "The Charles R. Drew Papers — Becoming “the Father of the Blood Bank,” 1938–1941",
      "url": "https://www.nlm.nih.gov/exhibition/education/charlesdrew/pdf/FatheroftheBloodBankBiography.pdf"
    },
    {
      "title": "Blood safety and availability",
      "url": "https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability"
    },
    {
      "title": "Massive hemorrhage and emergency transfusion",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/massive-hemorrhage-and-emergency-transfusion"
    },
    {
      "title": "ASH SCD Guidelines: Transfusion Support",
      "url": "https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/sickle-cell-disease-guidelines/scd-guidelines-transfusion-support"
    },
    {
      "title": "Sickle Cell Disease",
      "url": "https://www.hematology.org/education/patients/anemia/sickle-cell-disease"
    },
    {
      "title": "Choosing Wisely",
      "url": "https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely"
    },
    {
      "title": "Platelet transfusion, alloimmunization and management of platelet refractoriness",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/platelet-transfusion-alloimmunization-and-management-platelet"
    },
    {
      "title": "Expert Panel Recommends Liberal Transfusion Strategy for Hospitalized Patients With AMI",
      "url": "https://www.aabb.org/news-resources/news/article/2025/08/20/expert-panel-recommends-liberal-transfusion-strategy-for-hospitalized-patients-with-ami"
    },
    {
      "title": "Blood safety and availability",
      "url": "https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability/"
    },
    {
      "title": "Blood products: Blood donation",
      "url": "https://www.who.int/news-room/questions-and-answers/item/blood-products-why-should-i-donate-blood"
    },
    {
      "title": "Blood Donor Selection: Guidelines on Assessing Donor Suitability for Blood Donation",
      "url": "https://iris.who.int/bitstream/handle/10665/76724/9789241548519_eng.pdf"
    },
    {
      "title": "FAQs for first-time donors",
      "url": "https://www.blood.ca/en/blood/donating-blood/new-donor/first-time-donor-faqs"
    },
    {
      "title": "Donor selection, donor testing and pathogen reduction",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/donor-selection-donor-testing-and-pathogen-reduction"
    },
    {
      "title": "An overview of donor wellness and perspectives",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/overview-donor-wellness-and-perspectives"
    },
    {
      "title": "Canadian Blood Services Donation Testing",
      "url": "https://www.blood.ca/en/hospital-services/products/donation-testing"
    },
    {
      "title": "FAQs: Human Immunodeficiency Virus (HIV) testing",
      "url": "https://www.blood.ca/en/news-and-events/media-resources/hiv/faqs-human-immunodeficiency-virus-hiv-testing"
    },
    {
      "title": "Transfusion-Transmitted Malaria: Risk-Based Decision-Making Analysis",
      "url": "https://www.blood.ca/sites/default/files/MalariaRBDMAnalysis_FINAL_2024-05-28.pdf"
    },
    {
      "title": "Important Information for Blood Establishments and Transfusion Services Regarding Bacterial Contamination of Platelets for Transfusion",
      "url": "https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-information-blood-establishments-and-transfusion-services-regarding-bacterial-0"
    },
    {
      "title": "World Blood Donor Day - Who can give blood",
      "url": "https://www.who.int/campaigns/world-blood-donor-day/who-can-give-blood"
    },
    {
      "title": "Red Blood Cells",
      "url": "https://www.blood.ca/sites/default/files/IM-00005.pdf"
    },
    {
      "title": "CIRCULAR OF INFORMATION For the Use of Human Blood Components",
      "url": "https://www.blood.ca/sites/default/files/IM-00004_Revision_2.pdf"
    },
    {
      "title": "Irradiated, washed and CMV seronegative blood components",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/irradiated-washed-and-cmv-seronegative-blood-components"
    },
    {
      "title": "Pathogen-reduced platelets",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/pathogen-reduced-platelets"
    },
    {
      "title": "Red cell irradiation – time for a change?",
      "url": "https://www.blood.ca/en/hospital-services/transfusion-practice/research-units/red-cell-irradiation-time-change"
    },
    {
      "title": "A different way to look at red blood cell quality",
      "url": "https://www.blood.ca/en/hospital-services/transfusion-practice/research-units/different-way-look-red-blood-cell-quality"
    },
    {
      "title": "Canadian Blood Services quality control",
      "url": "https://www.blood.ca/en/hospital-services/products/component-manufacturing/quality-control"
    },
    {
      "title": "ABO",
      "url": "https://www.lifeblood.com.au/health-professionals/testing/blood-groups/ABO"
    },
    {
      "title": "Rh",
      "url": "https://www.lifeblood.com.au/health-professionals/testing/blood-groups/rh"
    },
    {
      "title": "Blood Essentials, version 2.0, June 2025",
      "url": "https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/36614/blood-essentials-v20-june-2025.pdf"
    },
    {
      "title": "Pretransfusion specimen collection and compatibility testing",
      "url": "https://prod2.lifeblood.com.au/health-professionals/clinical-practice/transfusion-process/pretransfusion-specimen-collection-compatibility-testing"
    },
    {
      "title": "Pre-transfusion testing",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/pre-transfusion-testing"
    },
    {
      "title": "Matching blood groups",
      "url": "https://www.lifeblood.com.au/patients-recipients/blood-plasma-platelets/blood-for-transfusion/matching-blood-groups"
    },
    {
      "title": "Management guide for emergency use of group O red blood cells",
      "url": "https://www.health.vic.gov.au/sites/default/files/2023-03/Management-guide-for-emergency-use-group-o-red-blood-cells.pdf"
    },
    {
      "title": "Aide-mémoire for National Health Authorities and Hospital Management: clinical transfusion process and patient safety",
      "url": "https://www.who.int/publications/i/item/WHO-EHT-10.05"
    },
    {
      "title": "Blood administration",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/blood-administration"
    },
    {
      "title": "Blood Transfusion: Blood administration",
      "url": "https://www.rch.org.au/bloodtrans/blood_administration/Blood_administration/"
    },
    {
      "title": "Monitoring and observation",
      "url": "https://www.lifeblood.com.au/health-professionals/clinical-practice/transfusion-process/monitoring-observation"
    },
    {
      "title": "Management of suspected reactions",
      "url": "https://www.lifeblood.com.au/health-professionals/clinical-practice/adverse-events/management-of-suspected-reactions"
    },
    {
      "title": "Haematology guideline, neonates",
      "url": "https://clinicalguidelines.scot.nhs.uk/ggc-paediatric-guidelines/ggc-paediatric-guidelines/neonatology/haematology-guideline-neonates/?searchTerm=lfts+in+asymptomatic"
    },
    {
      "title": "Neonatal and pediatric transfusion",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/neonatal-and-pediatric-transfusion"
    },
    {
      "title": "Neonatal transfusion guideline",
      "url": "https://www.clinicalguidelines.scot.nhs.uk/nhsggc-guidelines/nhsggc-guidelines/neonatology/neonatal-transfusion-guideline/"
    },
    {
      "title": "Neonatal Guidelines 2017–19",
      "url": "https://kids.bwc.nhs.uk/wp-content/uploads/2021/02/Neonatal-Guidelines-2017-19-A4-format-PDF.-Version-2-03.18.pdf"
    },
    {
      "title": "American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6988392/"
    },
    {
      "title": "Transfusion reactions",
      "url": "https://professionaleducation.blood.ca/en/transfusion/clinical-guide/transfusion-reactions"
    },
    {
      "title": "Cell Salvage Obstetrics Guideline 2024",
      "url": "https://wisdom.nhs.wales/health-board-guidelines/swansea-bay-maternity-file/cell-salvage-obstetrics-guideline-2024/"
    },
    {
      "title": "What can cause adverse events",
      "url": "https://www.lifeblood.com.au/health-professionals/clinical-practice/adverse-events/what-can-cause-adverse-events"
    },
    {
      "title": "Delayed haemolytic transfusion reactions (DHTR)",
      "url": "https://www.lifeblood.com.au/health-professionals/clinical-practice/adverse-events/DHTR"
    },
    {
      "title": "Transfusion-related acute lung injury (TRALI)",
      "url": "https://professionaleducation.blood.ca/en/transfusion/publications/transfusion-related-acute-lung-injury-trali"
    },
    {
      "title": "Transfusion-transmissible infections in Australia: 2025 Surveillance Report",
      "url": "https://www.kirby.unsw.edu.au/sites/default/files/documents/Transfusion-Transmissible-Infections-Annual-Surveillance-Report_2025.pdf"
    },
    {
      "title": "Safety Analysis of Extended Platelet Shelf-Life with Large-Volume Delayed Sampling on BACT/ALERT® VIRTUO® in Australia",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10535894/"
    },
    {
      "title": "Antigens and antibodies",
      "url": "https://prod2.lifeblood.com.au/health-professionals/testing/antigens-antibodies"
    },
    {
      "title": "Platelet disorders",
      "url": "https://prod2.lifeblood.com.au/health-professionals/clinical-practice/clinical-indications/platelet-disorders"
    },
    {
      "title": "Post-transfusion purpura (PTP)",
      "url": "https://www.lifeblood.com.au/health-professionals/clinical-practice/adverse-events/PTP"
    },
    {
      "title": "Transfusion-associated graft-versus-host disease (TA-GVHD)",
      "url": "https://www.lifeblood.com.au/health-professionals/clinical-practice/adverse-events/TA-GVHD"
    },
    {
      "title": "The urgent need to implement patient blood management: policy brief",
      "url": "https://www.who.int/publications/i/item/9789240035744"
    },
    {
      "title": "Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9994846/"
    },
    {
      "title": "Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11247274"
    },
    {
      "title": "Guidance on implementing patient blood management to improve global blood health status",
      "url": "https://iris.who.int/bitstream/handle/10665/380784/9789240104662-eng.pdf?sequence=1"
    },
    {
      "title": "Blood safety and availability",
      "url": "https://www.who.int/en/news-room/fact-sheets/detail/blood-safety-and-availability"
    },
    {
      "title": "Standards for Blood Banks and Transfusion Services",
      "url": "https://www.aabb.org/standards-accreditation/standards/blood-banks-and-transfusion-services"
    },
    {
      "title": "Blood: authorisations and safety reporting",
      "url": "https://www.gov.uk/guidance/blood-authorisations-and-safety-reporting"
    },
    {
      "title": "Become AABB-Accredited",
      "url": "https://www.aabb.org/standards-accreditation/accreditation/become-accredited"
    },
    {
      "title": "The Blood Safety and Quality (Amendment) Regulations 2006",
      "url": "https://www.legislation.gov.uk/uksi/2006/2013/pdfs/uksi_20062013_en.pdf"
    },
    {
      "title": "Global status report on blood safety and availability 2025",
      "url": "https://www.who.int/publications/b/82618"
    },
    {
      "title": "Patient consent and shared decision-making for blood transfusion: guidelines from the SaBTO expert advisory committee",
      "url": "https://www.gov.uk/government/publications/blood-transfusion-patient-consent/guidelines-from-the-expert-advisory-committee-on-the-safety-of-blood-tissues-and-organs-sabto-on-patient-consent-for-blood-transfusion"
    },
    {
      "title": "A guide to establishing a national haemovigilance system",
      "url": "https://www.who.int/publications/b/31380"
    },
    {
      "title": "Near Miss (NM) Cumulative Data",
      "url": "https://www.shotuk.org/resources/near-miss-nm-cumulative-data/"
    },
    {
      "title": "Surveillance Report",
      "url": "https://professionaleducation.blood.ca/en/transfusion/publications/surveillance-report"
    },
    {
      "title": "Blood system inventory management best practices guide",
      "url": "https://profedu.blood.ca/en/transfusion/best-practices/blood-utilization-best-practices/blood-system-inventory-management-best"
    },
    {
      "title": "About MINT",
      "url": "https://www.minttrial.org/about-mint/"
    },
    {
      "title": "RESTORE",
      "url": "https://www.nhsbt.nhs.uk/clinical-trials-unit/trials-and-studies/blood-and-transfusion/restore/"
    },
    {
      "title": "First ever clinical trial of laboratory grown red blood cells being transfused into another person",
      "url": "https://www.nhsbt.nhs.uk/news/first-ever-clinical-trial-of-laboratory-grown-red-blood-cells-being-transfused-into-another-person/?os=avefgi"
    },
    {
      "title": "Research: NIHR Blood and Transplant Research Unit in Red Blood Cell Products",
      "url": "https://www.bristol.ac.uk/btru/work/research/"
    },
    {
      "title": "Engineering red blood cells",
      "url": "https://www.nhsbt.nhs.uk/research-and-development/research-blogs/engineering-red-blood-cells/"
    },
    {
      "title": "INTERCEPT Blood System for Platelets",
      "url": "https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/intercept-blood-system-platelets"
    },
    {
      "title": "Package Insert: INTERCEPT Blood System for Platelets—Small Volume Processing Set, Semi-Integrated Set",
      "url": "https://www.fda.gov/media/190011/download?attachment="
    },
    {
      "title": "Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29392283/"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}